A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming

• Published in: Oncogene Vol. 41; no. 47; pp. 5076 - 5091
• Main Authors: Yousefi, Hassan, Khosla, Maninder, Lauterboeck, Lothar, Okpechi, Samuel C., Worthylake, David, Garai, Jone, Zabaleta, Jovanny, Guidry, Jessie, Zarandi, Mohammad Amin, Wyczechowska, Dorota, Jayawickramarajah, Janarthanan, Yang, Qinglin, Kissil, Joseph, Alahari, Suresh K.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 18.11.2022; Nature Publishing Group
• Subjects: 13/2; 13/31; 13/51; 13/95; 59; 59/5; 631/154/1435/2418; 631/67/1347; Antitumor agents; Apoptosis; Breast cancer; Cell Biology; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Doxorubicin - pharmacology; Doxorubicin - therapeutic use; Glycolysis; Human Genetics; Humans; Internal Medicine; Medicine; Medicine & Public Health; Metabolism; Next-generation sequencing; Oncology; Oxidative phosphorylation; Patients; Phosphorylation; Proteomics; Triple Negative Breast Neoplasms - genetics; Xenograft Model Antitumor Assays

Treatment of patients with triple-negative breast cancer (TNBC) has been challenging due to the absence of well-defined molecular targets and the highly invasive and proliferative nature of TNBC cells. Current treatments against TNBC have shown little promise due to high recurrence rate in patients....